Marimed INC 8-K filings

MariMed Inc. announced its second quarter 2026 financial results, highlighting record quarterly revenue and sequential growth in both wholesale and retail segments, alongside a continued net loss.

MariMed Inc. announced the results of its 2026 Annual Meeting of Stockholders, where four directors were re-elected and the appointment of M&K CPAs PLLC as independent auditors was approved on an advisory basis.

MariMed reports Q1 2026 revenue of $39.5 million, reflecting year-over-year growth and improved operational profitability.

MariMed Inc. has restructured a $14.2 million obligation to Navy Capital, converting it into $8 million in new promissory notes and 26.9 million shares of new convertible preferred stock.

MariMed Inc. reported a slight revenue increase to $40.8 million in Q3 2025, alongside a widened GAAP net loss of $2.9 million, while expanding its brand distribution.

MariMed Inc. reported mixed financial results for Q2 2025, with sequential revenue growth and increased Adjusted EBITDA, but year-over-year declines in revenue and gross margin, alongside strategic expansion into new markets.

MariMed Inc. announced that its stockholders re-elected four directors and approved the appointment of M&K CPAs PLLC as independent auditors for the 2025 fiscal year at its Annual Meeting held on June 12, 2025.

MariMed Inc. announces its Q1 2025 financial results, showing slight revenue growth offset by increased net losses, while highlighting strategic expansion and brand performance.

MariMed Inc. announces record revenues for Q4 and full year 2024, but reports a GAAP net loss despite growth in wholesale revenue and adjusted EBITDA.

MariMed Inc. announced its third quarter 2024 financial results, highlighting year-over-year and sequential revenue growth, along with updated full-year financial targets.

MariMed Inc. has appointed Mario Pinho as its new Chief Financial Officer, effective August 9, 2024, replacing interim CFO Jon Levine, who remains CEO.

MariMed Inc. announced strong revenue growth for the second quarter of 2024, driven by its wholesale business and a turnaround in retail transactions, while navigating margin pressures.

MariMed Inc. successfully held its 2024 Annual Meeting, re-electing all five directors and approving the appointment of M&K CPAs PLLC as independent auditors.

MariMed Inc. announced a revenue increase for Q1 2024, but experienced a decrease in profitability compared to the same period last year.

MariMed Inc. announced record revenue for 2023, driven by strong wholesale performance and new asset openings, while also expanding its presence in Maryland with a pending dispensary acquisition.